(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of 4.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Maravai Lifesciences Holdings's revenue in 2025 is $192,283,000.On average, 13 Wall Street analysts forecast MRVI's revenue for 2025 to be $48,377,175,357, with the lowest MRVI revenue forecast at $46,265,036,933, and the highest MRVI revenue forecast at $51,282,004,957. On average, 13 Wall Street analysts forecast MRVI's revenue for 2026 to be $52,752,319,235, with the lowest MRVI revenue forecast at $48,077,998,365, and the highest MRVI revenue forecast at $58,746,087,354.
In 2027, MRVI is forecast to generate $56,823,171,985 in revenue, with the lowest revenue forecast at $51,016,069,853 and the highest revenue forecast at $63,499,677,342.